Tumor-specific outcome (per individual patient) | |
Complete response | 8 (14%) |
Partial response | 13 (23%) |
Stable disease | 6 (11%) |
Progressive disease | 4 (7%) |
Unspecified | 25 (45%) |
Type of hyperinflammatory syndrome | |
CRS | 16 (28%) |
HLH | 34 (61%) |
other | 6 (11%) |
Type of ICI | |
Pembrolizumab | 21 (38%) |
Nivolumab | 11 (20%) |
Ipilimumab | 2 (4%) |
Atezolizumab | 2 (4%) |
Ipilimumab+nivolumab | 13 (23%) |
Cemiplimab | 1 (2%) |
Ipilimumab+pembrolizumab | 1 (2%) |
Sintilimab | 2 (4%) |
Unspecified | 3 (5%) |
CRS/HLH treatment with IL-6 blockade | |
Yes | 14 (25%) |
No | 42 (75%) |
Rechallenge with ICIs | |
Yes | 6 (11%) |
No | 31 (55%) |
Unspecified | 19 (34%) |
CRS/HLH outcome | |
Recovery | 43 (77%) |
Deceased, related to CRS/HLH | 6 (11%) |
Deceased, other reasons | 2 (4%) |
Unspecified | 5 (9%) |
Time to CRS/HLH onset | |
Days after last administration* | 9 (3,75-21) |
Cycles before symptoms onset* | 2(1-3) |
Type of underlying malignancy | |
Bladder cancer | 3 (5%) |
Lung cancer | 15 (27%) |
Malignant melanoma | 21 (38%) |
Renal cell carcinoma | 3 (5%) |
Other | 14 (25%) |
*Numbers given as mean with IQR
CRS, cytokine release syndrome; HLH, hemophagocytic lymphohistiocytosis; ICI, immune-checkpoint inhibitor.